Raymed Labs Ltd Stock Price Today (NSE: RAYLA)
Fundamental Score
Raymed Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Raymed Labs Ltd share price today is ₹3.83, up +0.00% on NSE/BSE as of 18 June 2026. Raymed Labs Ltd (RAYLA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.64 (Cr). The 52-week high for RAYLA share price is ₹3.83 and the 52-week low is ₹3.48.
Raymed Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Raymed Labs Ltd share price chart: 4.93% return over the past month. 52-week high ₹3.83, 52-week low ₹3.48.
Raymed Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 0.00 (Cr) | |
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | 1.00 (Cr) | |
| ₹3.65 | ₹3.65 | ₹3.65 | ₹3.65 | 0.00 (Cr) |
Raymed Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹3.83 | ₹3.83 | ₹3.83 | ₹3.83 | +0.00% | |
| ₹3.65 | ₹3.83 | ₹3.65 | ₹3.83 | +4.93% | |
| ₹3.65 | ₹3.65 | ₹3.65 | ₹3.65 | +0.00% | |
| ₹3.48 | ₹3.65 | ₹3.48 | ₹3.65 | +4.89% | |
| ₹3.48 | ₹3.65 | ₹3.48 | ₹3.48 | +0.00% | |
| ₹3.48 | ₹3.48 | ₹3.48 | ₹3.48 | +0.00% | |
| ₹3.32 | ₹3.48 | ₹3.32 | ₹3.48 | +4.82% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Zero revenue, negative cash flow, micro-cap pharma play trading on hope – avoid until proven otherwise.
WHAT'S HAPPENING NOW
No major catalysts found after live search. Last news mentions are from early April, regarding general pharma sector trends.
CORE STORY
This is a micro-cap pharma stock trading on hope, not current earnings. The market is likely pricing in future growth potential tied to the broader India pharma innovation narrative.
- India pharma sector hype
- Micro-cap momentum
- Low float can cause price swings
- Major order announcement
- Acquisition by larger pharma player
- Positive earnings surprise
- Zero revenue
- Negative free cash flow of ₹-2.25 Cr
- Micro-cap liquidity risk
No change in FII/DII holdings. Promoter holding stable at 32.27%.
India pharma sector is a tailwind, but Raymed needs to execute.
No. Negative free cash flow of ₹-2.25 Cr.
Hope for a contract win or acquisition in the next 3-6 months. Highly speculative.
Primary Thesis Risk
Lack of revenue and negative cash flow make this a high-risk speculation.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Raymed Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Raymed Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of RAYLA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Robust Profit Growth (50.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Weak Interest Coverage (-1.55x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-2.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.96%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Raymed Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Raymed Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Raymed Labs LtdRaymed Labs Ltd...Selected✓ RAYLA • 531207 | 8/100 | ₹3.83₹4 | ₹1.64₹1.64 | — — | — — | — — | — — | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Raymed Labs Ltd Quarterly Performance
Latest quarterly metrics for RAYLA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
50.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Raymed Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for RAYLA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Raymed Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Raymed Labs Ltd (RAYLA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Raymed Labs Ltd
About RAYLA (Raymed Labs Ltd)
Raymed Labs Ltd (RAYLA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current m...arket capitalisation of ₹1.64 (Cr). Investors tracking RAYLA share price can monitor key metrics including P/E ratio, promoter holding of 32.27%, and quarterly earnings growth.
Company Details
RAYLA Share Price: Frequently Asked Questions
What is the current share price of Raymed Labs Ltd?
Raymed Labs Ltd (RAYLA) trades at ₹3.83 on NSE and BSE. Market cap ₹1.64 (Cr). Educational data only.
What is the P/E ratio of Raymed Labs Ltd?
Raymed Labs Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Raymed Labs Ltd?
Raymed Labs Ltd has a Bull Run score of 8/100 based on 25+ financial parameters.
Does Raymed Labs Ltd pay dividends?
Raymed Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Raymed Labs Ltd?
Raymed Labs Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Raymed Labs Ltd?
Raymed Labs Ltd has debt-to-equity of N/A.
Is Raymed Labs Ltd a good investment?
Bull Run gives Raymed Labs Ltd a score of 8/100. This is not investment advice — consult a SEBI-registered advisor.